BioNexus Gene Lab Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549 

FORM 8-K

CURRENT REPORT 

Pursuant to Section 13 or Section 15(d) 

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 12, 2024 (September 11, 2024)

Registrant’s telephone number, including area code: +1 307 241 6898 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions: 

Securities registered or to be registered pursuant to Section 12(b) of the Act. 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure

On September 11, 2024, BioNexus Gene Lab Corp (the “Company”) issued a press release announcing that its subsidiary, Chemrex Corporation Sdn Bhd., a Malaysian corporation and a wholly owned subsidiary of the Company (“Chemrex”), has invested RM 2 million (approx. USD $450,000) to commence production of fine-quality color paste (non-drying type) for composite industrial customers, with operations set to begin in September 2024. The press release outlines the advantages of this new production line, including increased profit margins, improved quality control, timely delivery of products, competitive pricing, and market opportunities in Southeast Asia, the Middle East, Australia, and New Zealand.

The press release also highlights future expansion plans for the establishment of additional production facilities in the Middle East and Vietnam, as well as synergies created through bulk purchasing of raw materials to enhance cost efficiency and expand into new industries. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

On September 12, 2024, the Company issued a press release announcing that that its wholly owned subsidiary MRNA Scientific Sdn. Bhd. (“MRNA Scientific”) has signed a strategic partnership Memorandum of Understanding with Shenzhen Rongguang Health Group, a leading healthcare provider in China. The collaboration aims to expand expertise in cancer screening, precision medicine, and preventative healthcare, focusing on early detection, personalized health solutions, and chronic disease management.

Through MRNA Scientific, the Company will enhance cancer screening across Southeast Asia and China, while both companies will jointly develop regenerative medicine technologies and preventative care solutions. A copy of the press release is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits  

(d) Exhibits 

SIGNATURES 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.